NTproBNP levels can predict future events in non-severe AS, JAMA study.

Is non-severe aortic stenosis (AS) really as benign as we think? Recent studies have questioned the presumed low-risk status of patients with asymptomatic non-severe aortic stenosis (AS). This calls for a novel marker to risk stratify non-severe AS patients into those at high clinical risk and those at lower risk for disease progression.
In the recent issue of JAMA Cardiology, researchers Hadziselimovic et al have proposed a new risk marker for AS i.e. NT proBNP and have shown that NT-proBNP concentrations within the reference range at year 1 are associated with low clinical risk in patients with asymptomatic nonsevere AS. Conversely, an increased 1-year NT-proBNP level may be associated with high aortic valve events (AVE) rates.
Analysis of annual NT-proBNP concentrations in the multicenter, double-blind Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) randomized clinical trial was performed. SEAS included 1873 patients with asymptomatic AS not requiring statin therapy with transaortic maximal flow velocity from 2.5 to 4.0 m/s and preserved ejection fraction.
Aortic valve events (AVEs), which are a composite of aortic valve replacement, cardiovascular death, or incident heart failure due to AS progression, were noted. Landmark analyses from year 1 examined the association of NT-proBNP concentrations with outcomes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.